For patients with BRAF V600E positive lung cancer and recent PE/DVT, is there any contraindication to BRAF/MEK inhibitor therapy?

This is a good question and not an uncommon clinical scenario. The first question is whether the PE/DVT is attributable to treatment with MEKi or to the underlying cancer or other provoked risk factors (surgery, limited mobility, hospitalization, etc). In the phase 2 trial of dabrafenib and trametin...